Yes, elevated red blood cell counts with increased hemoglobin and hematocrit substantially increase thrombotic risk.
Elevated RBC parameters directly promote both arterial and venous thrombosis through multiple mechanisms, and this risk is particularly pronounced in myeloproliferative neoplasms like polycythemia vera where thrombosis represents a major cause of morbidity and mortality 1, 2, 3.
Mechanisms of Increased Thrombotic Risk
The prothrombotic effects of elevated RBC counts operate through both biophysical and biochemical pathways:
Biophysical Mechanisms
- Enhanced platelet margination: Higher RBC counts physically push platelets toward vessel walls, increasing their contact frequency and duration with sites of vascular injury 2
- Increased blood viscosity: Elevated hematocrit raises blood viscosity, which alters shear stress patterns and promotes platelet activation 1, 4
- Accelerated thrombus formation: Experimental models demonstrate that elevated hematocrit shortens vessel occlusion time and increases the rate of thrombus formation 2
Biochemical Mechanisms
- Platelet activation: RBCs release ATP and ADP, which directly activate platelets 1
- Altered fibrin structure: RBCs modify fibrin architecture, creating thrombi that are more resistant to fibrinolysis 4
- Nitric oxide depletion: Hemolysis and RBC dysfunction reduce nitric oxide bioavailability, impairing vasodilation 4
Clinical Context: Polycythemia Vera
When evaluating erythrocytosis, the critical distinction is whether this represents polycythemia vera (PV), as this myeloproliferative neoplasm carries particularly high thrombotic risk 5, 6.
Diagnostic thresholds for PV per WHO 2016 criteria 5:
- Hemoglobin >16.5 g/dL (men) or >16 g/dL (women)
- Hematocrit >49% (men) or >48% (women)
- Plus JAK2 mutation and supporting criteria
Important Caveat: Iron Deficiency Masking
Iron deficiency can mask PV by lowering hemoglobin/hematocrit below diagnostic thresholds while RBC count remains elevated 7. Look for microcytosis (low MCV) with elevated RBC count and high-normal or slightly elevated hemoglobin—this combination should prompt JAK2 testing even when hematocrit appears borderline 7, 8. The hematocrit-to-hemoglobin ratio (HHR) >3.1 may indicate iron-deficient PV and independently predicts thrombosis risk 9.
Quantifying the Risk
- In experimental models, elevated hematocrit increases platelet deposition rates and accelerates thrombus growth at arterial shear rates 2
- PV patients with higher HHR (suggesting iron deficiency and stronger myeloproliferation) show 5-fold increased thrombosis risk (HR 5.20) independent of traditional high-risk classification 9
- Thrombosis remains a leading cause of morbidity in PV, affecting both arterial and venous circulations 5
Clinical Implications
Any patient with unexplained erythrocytosis requires evaluation for underlying myeloproliferative neoplasm, particularly when presenting with unprovoked thrombosis 10, 7. The association between elevated RBC parameters and thrombosis is not merely correlative—mechanistic studies confirm RBCs actively promote thrombus formation and stability 1, 3, 4.
Key red flags warranting JAK2 testing:
- Unprovoked arterial or venous thrombosis with any degree of erythrocytosis
- Elevated RBC count with microcytosis and high-normal hemoglobin
- Splenomegaly with erythrocytosis
- Leukocytosis or thrombocytosis accompanying erythrocytosis
The thrombotic risk from elevated RBC parameters is real, mechanistically established, and clinically significant—particularly when representing an underlying clonal myeloproliferative disorder rather than secondary erythrocytosis 1, 2, 3.